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A B S T R A C T
Mucopolysaccharidosis type I (MPS I) is a rare inherited metabolic disorder caused by defects in alpha-L-iduronidase (IDUA), a lysosomal protein encoded by IDUA
gene. MPS I is a progressive multisystemic disorder with a wide range of symptoms, including skeletal abnormalities and cognitive impairment, and is characterized
by a wide spectrum of severity levels caused by varied mutations in IDUA. A human iPSC line was established from an attenuated MPS I (Scheie syndrome) patient
carrying an IDUA gene mutation (c.266G > A; p.R89Q). This disease-specific iPSC line will be useful for the research of MPS I.
Resource table
Unique stem cell line identifier BRCi001-A
Alternative name of stem cell line HPS0660
Institution RIKEN BioResource Research Center (BRC), Kyoto, Japan
Contact information of distributor Haruhisa Inoue
haruhisa.inoue@riken.jp
Type of cell line iPSC
Origin Human
Additional origin info Age: 47 years of age
Sex: female
Ethnicity: Japanese
Cell source Peripheral blood mononuclear cells (PBMCs)
Clonality Clonal
Method of reprogramming Episomal vectors (SOX2, KLF4, OCT4, L-MYC, LIN28, p53 carboxy-terminal dominant-negative fragment (mp53DD), EBNA1)
Genetic modification Yes
Type of modification Hereditary
Associated disease Mucopolysaccharidosis type I (MPS I, Scheie syndrome)
Gene/locus IDUA gene/Chromosome 4
Method of modification Not available
Name of transgene or resistance Not available
Inducible/constitutive system Not available
Date archived/stock date Dec 2014
Cell line repository/bank RIKEN BioResource Research Center (BRC), Japan
http://en.brc.riken.jp/index.html
cellbank.brc@riken.jp
Ethical approval Ethics Committee of the RIKEN BioResource Research Center (approved No. Tsukuba 29–1)
Ethics Committee of the Department of Medicine and the Graduate School of Medicine of Kyoto University (approved No. R0091, G259)
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MPS I is an autosomal recessive disorder caused by mutations of the
IDUA gene. The disease pathophysiology is not well understood. iPSCs
were generated from an MPS I patient with an IDUA gene mutation
(c.266G > A; p.R89Q). These disease-specific iPSCs will be used to
study the pathological mechanisms of MPS I.
Resource details
Mucopolysaccharidosis Type I (MPS I) is a lysosomal storage dis-
order caused by mutations of the alpha-L-iduronidase (IDUA) gene
(Poletto et al., 2018; Yamagishi et al., 1996). The condition affects
many parts of the body, including the brain, musculoskeletal system,
heart, lungs, and eyes. Mutations of the IDUA gene lead to IDUA en-
zyme deficiency, resulting in the accumulation of glycosaminoglycans
(GAGs), heparan sulfate and dermatan sulfate in cells and especially in
lysosomes. This causes many organs and tissues of the body to become
enlarged in MPS I. More than one hundred different mutations of the
IDUA gene have been identified in individuals with MPS I. These var-
iations result in a broad range of severity levels and disease progression
patterns among individuals with MPS I (Poletto et al., 2018; Yamagishi
et al., 1996). However, the disease pathophysiology is largely unknown.
MPS I-specific iPSCs can be used to understand the pathophysiological
mechanism of MPS I. We established and characterized an iPSC line
from a patient with attenuated MPS I who carried an IDUA gene mu-
tation (c.266G > A; p.R89Q). MPS I-specific iPSCs were generated
from peripheral blood mononuclear cells (PBMCs) of an MPS I patient
using episomal vectors carrying reprogramming factors under feeder-
free culture conditions (Nakagawa et al., 2014; Okita et al., 2013). The
MPS I-specific iPSC (HPS0660) presented a human ES cell-like mor-
phology. The iPSCs were found to be positive for pluripotent marker
NANOG and SSEA4 by immunocytochemistry (Fig. 1A, green: NANOG,
red: SSEA4), and 99.9% of the iPSCs were found to be positive for
pluripotent marker SSEA4 by flow cytometry. The three-germ-layer
differentiation capacities of the iPSCs were revealed with an in vitro EB
Fig. 1. Characterization of the iPSC line.
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formation assay (Fig. 1C, Tubulin βIII: ectoderm, D, SOX17: endoderm,
and E, smooth muscle actin (SMA): mesoderm). Furthermore, the iPSCs
retained the IDUA gene mutation and normal karyotype. The identity of
the cell line was verified with an STR analysis. Mycoplasma con-
tamination was not detected in the cell culture.
Materials and methods
Ethics statement
The generation and use of human iPSCs was approved of by Ethics
Committees of RIKEN BioResource Research Center, Department of
Medicine and Graduate School of Medicine of Kyoto University. All
methods used in this study were performed in accordance with approved
guidelines. Formal informed consent was obtained from the patient.
Establishment of iPSCs
The iPSCs were generated from peripheral blood mononuclear cells
(PBMCs) obtained from a patient with attenuated MPS I, according to
the protocol for the generation and culture of human iPSCs under
feeder-free conditions (Nakagawa et al., 2014, http://www.cira.kyoto-
u.ac.jp/e/research/protocol.html). In brief, the PBMCs were cultured
for 5 days in MNC medium; StemSpan-ACF medium (STEMCELL
Technologies, Vancouver, Canada), supplemented with 100 ng/ml
rhSCF, 100 ng/ml rhTPO, 100 ng/ml rhFlt3L, 50 ng/ml rhIL-6, 20 ng/
ml rhIL-3 (all from R&D Systems, Minneapolis, MN). The episomal
vectors (pCE-hOCT3/4 [0.63 μg], pCE-hSK [SOX2 and KLF4, 0.63 μg],
pCE-hUL [L-MYC and LIN28, 0.63 μg], pCE-mp53DD [p53 carboxy-
terminal dominant-negative fragment, 0.63 μg], and pCXB-EBNA1
[0.5 μg]) were transduced into PBMCs (3,000,000 cells) by electro-
poration using the Nucleofector 2b Device with a Human CD34+ Cell
Nucleofector Kit (Lonza, Basel, Switzerland). The electroporated cells
were plated in MNC medium on iMatrix-511 E8 fragment (MATRIX-
OME, Osaka, Japan)-coated cell culture plates and cultured in a CO2
incubator at 37 °C under 5% CO2. For two to eight days after the
electroporation, an equal volume of StemFit medium was added to the
culture wells every other day without aspiration, then the culture
medium was replaced with StemFit medium to induce iPSCs. The cells
were cultured in the CO2 incubator at 37 °C under 5% CO2 for
14–18 days until iPSC colonies were observed. The selected iPSC clone
was expanded and maintained using StemFit medium and iMatrix-511
E8 fragment (Nakagawa et al., 2014). The iPSCs were single-cell pas-
saged every 6–8 days using 0.5× TrypLE Select (TrypLE Select (Gibco,
Thermo Fisher, Waltham, MA) diluted 1:1 with 0.5 mM EDTA solution).
The plating density was 1350 cells per cm2. 10 μM Y-27632 (Wako,
Osaka, Japan) was added to StemFit medium when the iPSCs were
passaged, and was removed by replacing the medium with fresh
StemFit medium the next day.
Karyotyping
A G-band analysis was performed by LSI Medience (Tokyo, Japan)
to determine the karyotype of the iPSC line at passage number 6. A total
of 20 metaphases were analyzed.
Genotyping
Genomic DNA of undifferentiated state iPSCs at passage number 4
and the parental PBMCs was extracted using a PureLink Genomic DNA
Mini Kit (Invitrogen, Thermo Fisher Scientific) and amplified by a PCR
using the enzyme KOD Plus Neo (TOYOBO, Japan) and Veriti thermal
cycler (Applied Biosystems, Thermo Fisher Scientific). The thermo-
cycling conditions were as follows: initial denaturation at 94 °C for
2min, 35 cycles of 2-step thermocycling (denaturation at 98 °C for 10 s
and extension at 68 °C for 30 s), and hold at 10 °C. The targeted PCR
product was extracted from agarose gel using a PureLink Quick Gel
Extraction Kit (Invitrogen, Thermo Fisher Scientific) and then subjected
to direct sequencing using a BigDye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems, Thermo Fisher Scientific) according to man-
ufacturers' instructions. A 3500xL Genetic Analyzer (Applied
Biosystems, Thermo Fisher Scientific) was used for the sequencing
analyses. The primer set used for genotyping is listed in Table 2.
In vitro three-germ-layer differentiation assay
An embryoid body (EB) formation assay was performed to differ-
entiate iPSCs into three germ layers. EBs were formed from the 0.5×
TrypLE Select-dissociated iPSCs (9000 cells per EB) in DMEM/F12
medium supplemented with 20% KSR, 2mM L-glutamine, 0.1 mM
NEAA, 0.1 mM 2-mercaptoethanol (All from Gibco, Thermo Fisher
Scientific), 10 μM Y-27632 (Nacalai Tesque, Kyoto, Japan) using a low-
attachment surface V-bottom 96-well plate (Sumitomo Bakelite, Tokyo,
Japan) for 11 days, and then cultured in DMEM containing 10% FBS
(Gibco, Thermo Fisher Scientific) on a Matrigel (BD Bioscience)-coated
tissue culture plate for 7 days Table 1.
Immunocytochemistry
Indirect fluorescent immunostaining was performed. Cells were
fixed in 4% paraformaldehyde (Nacalai Tesque) in PBS for 20min at
room temperature. For permeabilization and blocking, the fixed cells
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal, human ESC like morphology Fig. 1 panel A
Phenotype Qualitative analysis
(Immunocytochemistry)
Positive staining of pluripotency markers, NANOG, SSEA-4 Fig. 1 panel A
Quantitative analysis (Flow cytometry) 99.9% of positive cells for pluripotency cell surface marker SSEA-
4
Fig. 1 panel B
Genotype Karyotype (G-banding) and resolution 46XX, Resolution 400 Fig. 1 panel G
Identity Microsatellite PCR (mPCR) Not performed Not performed
STR analysis 16 loci, matched Available with the authors
Mutation analysis (if applicable) Sequencing Homozygous IDUA mutation (c.266 G > A, p. R89Q) Fig. 1 panel F
Southern Blot or WGS Not performed Not performed
Microbiology and virology Mycoplasma Mycoplasma testing by indirect DNA fluorescent staining and RT-
PCR. Negative
Supplementary Fig. 1
Differentiation potential Embryoid body formation Proof of three-germ-layer formation: Tubulin βIII (ectoderm),
SOX17 (endoderm) and smooth muscle actin (mesoderm)
Fig. 1 panel C, D and E
Donor screening (OPTIONAL) HIV, HTLV-1, Hepatitis B, Hepatitis C Negative Available with the authors
Genotype additional info
(OPTIONAL)
Blood group genotyping Not available Not available
HLA tissue typing Not available Not available
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were incubated with blocking buffer: PBS containing 5% Blocking One
(Nacalai Tesque) and 0.2% Triton-X 100 (Nacalai Tesque). The primary
and secondary antibodies used in this study are listed in Table 2. Pri-
mary antibodies and secondary antibodies were reacted in the blocking
buffer for 16 h (overnight) at 4 °C and for 1 h at room temperature,
respectively. Nuclei were stained with DAPI (Invitrogen, Thermo Fisher
Scientific). Images were obtained with a BZ-X710 microscope (Keyence,
Osaka, Japan).
Flow cytometry
The iPSCs were dissociated with Accumax solution (Sigma Aldrich,
St. Louis, MO). The dissociated iPSCs were suspended in PBS containing
2% FBS (Stain buffer, BD Bioscience, San Jose, CA) at a density of
1.0× 106 cells/ml. The cells were stained for 30min on ice and ana-
lyzed with FACS Aria (BD Bioscience). The Alexa Fluor 647-labeled
antibodies used for flow cytometry are listed in Table 2. The FlowJo
software program (ver.10, FLOWJO, BD Bioscience) was used for the
data analysis.
STR analysis
Genomic DNA was extracted from the iPSCs and PBMCs using a
PureLink Genomic DNA Mini Kit and subjected to an STR analysis using
PowerPlex® 16 System (Promega, Madison, WI).
Mycoplasma test
iPSCs were confirmed to be mycoplasma-negative by indirect DNA
fluorescent staining and a nested-PCR. iPSC culture medium was tested by
staining with Hoechst33258 (Thermo Fisher Scientific) after 5–6 days of
co-culture with VERO cells (RCB0001, RIKEN BRC Cell Bank) as myco-
plasma negative indicator cells. DNA was extracted and subjected to a
nested-PCR. The primers used in the PCR are listed in Table 2. AmpliTaq
Gold 360 DNA Polymerase (Thermo Fisher Scientific) was used for each
step of the PCR. The same thermocycling conditions were used for both
steps: initial denaturation of 10min at 95 °C, 30 cycles of thermocycling;
30 s at 95 °C; 2min at 55 °C; 2min at 72 °C, final extension of 5min at
72 °C, and hold at 10 °C. The PCR products were detected by electro-
phoresis on 2% agarose gel and ethidium bromide staining.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2019.101406.
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Target Forward/Reverse primer (5′-3′)
Genotyping IDUA gene sequencing (498 bp) CTTGAACGTGTGTGTCAGCC/GACACACACAGGGATGCTCA
Nested-PCR, 1st step PCR (MCGpF11/MCGpR1) mycoplasma detection (200–400 bp) ACACCATGGGAG(C/T)TGGTAAT/CTTC(A/T)TCGACTT(C/T)CAGACCCAAGGCAT
Nested-PCR, 2nd step PCR (R16–2/MCGpR21) mycoplasma detection (200–400 bp) GTG(C/G)GG(A/C)TGGATCACCTCCT/GCATCCACCA(A/T)A(A/T)AC(C/T)CTT
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